The global helicobacter pylori infections treatment market is poised for substantial expansion, with an estimated value of US$ 638.3 Million expected in 2023. This growth trajectory is anticipated to persist, with a projected Compound Annual Growth Rate (CAGR) of 7.04% from 2023 to 2033, ultimately reaching an impressive US$ 1,260 Million.
The proliferation of Helicobacter pylori infections can be attributed to various factors, including inadequate water supply, poor sanitation, a burgeoning global population, and suboptimal personal hygiene. Notably, increased awareness of H. pylori infections within the population has emerged as a crucial factor influencing the growth of the Helicobacter pylori diagnostics market.
Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16291
Key Factors Driving Industry Growth:
- Antibiotic Availability and Affordability: The accessibility and affordability of antibiotics are expected to play a pivotal role in boosting their usage. This, in turn, will drive the demand for pre and post-surveillance tests, fostering growth in the overall industry.
- Quicker Processing Times: Technological advancements facilitating quicker processing times for diagnostic tests are anticipated to further stimulate the use of antibiotics and enhance the efficiency of H. pylori infection management.
- Rising H. Pylori Infection Rates: The escalating rates of H. pylori infections globally contribute to the heightened demand for effective treatments and diagnostics. This trend is expected to sustain industry growth over the forecast period.
- Need for Early Symptom Diagnosis: With a growing emphasis on early symptom diagnosis, there is an increasing demand for diagnostic methods that can swiftly and accurately detect H. pylori infections, driving the market forward.
The evolving landscape of the helicobacter pylori infections treatment industry presents opportunities for healthcare providers, pharmaceutical companies, and diagnostic technology developers. Stakeholders are urged to stay abreast of emerging trends and capitalize on the expanding market to contribute to the effective management of H. pylori infections globally.
Key Takeaways from Market Study:
- Global helicobacter pylori treatment market to expand nearly 2x from 2023 to 2033
- By 2023, Europe is expected to have the second-highest H. pylori sales volume, with 30% revenue.
- In terms of total revenue, hospitals and diagnostics laboratories accounted for more than 82% of the industry share in 2021.
- The global helicobacter pylori infections market is expected to be worth US$ 1,260 Million
- The global market for helicobacter pylori infections is estimated to be worth US$ 638.3 Million
“With a rise in the prevalence of chronic diseases, demand for helicobacter pylori treatment is rising, paving way for new approaches to treatment and therapeutics,” Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Request Methodology Now: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16291
Market Competition:
- Phathom Pharmaceuticals
- Redhill Biopharma
- Takeda Pharmaceuticals
- AbbVie
- Cumberland Pharmaceuticals
- Eisai Co.
- Bio-Rad Laboratories
- F. Hoffmann-La Roche
- Alpha Laboratories
- Biohit
Recent Development:
- In May 2022, Biomerica, Inc. received CE Mark for its hp+detect diagnostic test for Helicobacter pylori bacteria. Following product registration in each nation where it is sold, the company plans to market and sell its hp+detect diagnostic test in the European Union (EU) and other international markets.
- Otsuka launched QuickNaviTM-H. Pylori, a Helicobacter pylori Quick Detection Kit, in April 2021. The diagnostic kit employs the immunochromatography technique to determine the presence or absence of Helicobacter pylori antigens in a stool sample.
- In July 2022, Bio Rad introduced Platelia H. pylori IgG, an immuno-enzymatic assay for qualitative determination of IgG antibodies. Serology is a non-invasive, delicate, and simple method for determining H. pylori infection. To evaluate the quality of IgG antibodies, the Platelia H. pylori IgG immunoenzymatic assay is used.
Get a Purchase on the Report: https://www.futuremarketinsights.com/checkout/16291
Key Segments Profiled in the Helicobacter pylori infections treatment industry Survey:
By Treatment:
- Bismuth-quadruple Therapy
- Concomitant Therapy
- Levofloxacin Triple Therapy
- Bismuth Therapy
- High-dose Dual Therapy
By Application:
- Hospitals
- Diagnostics Laboratories
- Clinics
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
